Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
livmarli
mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - citas zāles žults sistēmas slimību ārstēšanai - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.
Eiropas Savienība -
latviešu -
EMA (European Medicines Agency)
bylvay
albireo - odevixibat - cholestasis, intrahepatic - Žults un aknu terapija - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 un 5.